{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T16:56:55Z","timestamp":1791219415237,"version":"4.1.0"},"reference-count":36,"publisher":"BMJ","issue":"10","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2026,8,11]]},"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:p>Abemaciclib, a cyclin-dependent kinase 4\/6 inhibitor (CDK4\/6i) for oestrogen receptor-positive (ER+) and human epidermal growth factor receptor 2-negative (HER2\u2212) breast cancer can rarely cause severe liver injury. We report a fatal case of abemaciclib-induced mixed hepatocellular-cholestatic injury progressing to liver failure. A Hispanic woman in her mid-60s with metastatic ER+\/HER2\u2013 breast cancer developed progressive hepatocellular-cholestatic injury 1\u2009month after starting abemaciclib with letrozole. She presented with jaundice, pruritus and dark urine. Labs showed markedly elevated bilirubin, liver enzymes and alkaline phosphatase. Liver biopsy revealed portal inflammation, bile duct injury, cholestasis and steatosis. Extensive work-up excluded other causes. Despite initial fall in transaminases with drug withdrawal and high-dose steroids, her condition progressed with rising bilirubin and worsening coagulopathy signalling progressive loss of hepatic synthetic function suggestive of impending liver failure and death. In clinical trial, any-grade transaminase elevation occurs in 14%\u201315% of patients receiving abemaciclib, with grade 3 hepatotoxicity in 2.9%\u20134.8%. In a retrospective cohort of patients receiving abemaciclib plus endocrine therapy, 29% (15\/52) developed abemaciclib-induced liver injury (AILI), with age \u226565 years, fatty liver disease and concomitant aromatase inhibitor use identified as risk factors. Educating patients to recognise early symptoms of liver injury is essential for prompt detection and management of AILI. This case highlights the need for patient education, close liver monitoring, early cessation of abemaciclib and consideration of genetic risk factors in high-risk patients.<\/jats:p>","DOI":"10.1136\/bcr-2025-268777","type":"journal-article","created":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T16:10:27Z","timestamp":1791216627000},"page":"e268777","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Fatal drug-induced liver injury in the setting of abemaciclib therapy for metastatic breast cancer"],"prefix":"10.1136","volume":"19","author":[{"given":"Ranjini","family":"Vengilote","sequence":"first","affiliation":[{"name":"Internal Medicine, Rochester General Hospital, Rochester, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed Usman","family":"Ehsanullah","sequence":"additional","affiliation":[{"name":"Hematology Oncology, Rochester General Hospital, Rochester, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehul","family":"Patel","sequence":"additional","affiliation":[{"name":"Lipson Cancer Institute, Rochester General Hospital, Rochester, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,10,5]]},"reference":[{"key":"2026100509101515000_19.10.e268777.1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2017.73.7585"},{"key":"2026100509101515000_19.10.e268777.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607303"},{"key":"2026100509101515000_19.10.e268777.3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.75.6155"},{"key":"2026100509101515000_19.10.e268777.4","doi-asserted-by":"publisher","DOI":"10.1002\/onco.13531"},{"key":"2026100509101515000_19.10.e268777.5","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.16114"},{"key":"2026100509101515000_19.10.e268777.6","doi-asserted-by":"publisher","DOI":"10.1136\/flgastro-2021-101886"},{"key":"2026100509101515000_19.10.e268777.7","unstructured":"Roussel Uclaf causality assessment method (RUCAM) in drug induced liver injury. In: LiverTox: clinical and research information on drug-induced liver injury. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases, 2019."},{"key":"2026100509101515000_19.10.e268777.8","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24108488","article-title":"Abemaciclib, Palbociclib, and Ribociclib in Real-World Data: A Direct Comparison of First-Line Treatment for Endocrine-Receptor-Positive Metastatic Breast Cancer","volume":"24","author":"Cejuela","year":"2023","journal-title":"Int J Mol Sci"},{"key":"2026100509101515000_19.10.e268777.9","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21061960","article-title":"The Roles of Cyclin-Dependent Kinases in Cell-Cycle Progression and Therapeutic Strategies in Human Breast Cancer","volume":"21","author":"Ding","year":"2020","journal-title":"Int J Mol Sci"},{"key":"2026100509101515000_19.10.e268777.10","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)71159-3"},{"key":"2026100509101515000_19.10.e268777.11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1911149"},{"key":"2026100509101515000_19.10.e268777.12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1609709"},{"key":"2026100509101515000_19.10.e268777.13","doi-asserted-by":"crossref","DOI":"10.1177\/17588359231205848","article-title":"CDK4\/6 inhibitors: basics, pros, and major cons in breast cancer treatment with specific regard to cardiotoxicity - a narrative review","volume":"15","author":"Pavlovic","year":"2023","journal-title":"Ther Adv Med Oncol"},{"key":"2026100509101515000_19.10.e268777.14","doi-asserted-by":"crossref","first-page":"5590","DOI":"10.21037\/apm-21-1096","article-title":"Side effects of CDK4\/6 inhibitors in the treatment of HR+\/HER2- advanced breast cancer: a systematic review and meta-analysis of randomized controlled trials","volume":"10","author":"Yang","year":"2021","journal-title":"Ann Palliat Med"},{"key":"2026100509101515000_19.10.e268777.15","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.123.029361","article-title":"Adverse Cardiovascular Events Associated With Cyclin-Dependent Kinase 4\/6 Inhibitors in Patients With Metastatic Breast Cancer","volume":"12","author":"Fradley","year":"2023","journal-title":"J Am Heart Assoc"},{"key":"2026100509101515000_19.10.e268777.16","doi-asserted-by":"publisher","DOI":"10.1080\/14737140.2019.1674651"},{"key":"2026100509101515000_19.10.e268777.17","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2019.01235","article-title":"Strategies for Early Prediction and Timely Recognition of Drug-Induced Liver Injury: The Case of Cyclin-Dependent Kinase 4\/6 Inhibitors","volume":"10","author":"Raschi","year":"2019","journal-title":"Front Pharmacol"},{"key":"2026100509101515000_19.10.e268777.18","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1378090","article-title":"CDK4\/6 inhibitors in drug-induced liver injury: a pharmacovigilance study of the FAERS database and analysis of the drug-gene interaction network","volume":"15","author":"She","year":"2024","journal-title":"Front Pharmacol"},{"key":"2026100509101515000_19.10.e268777.19","doi-asserted-by":"crossref","DOI":"10.14309\/crj.0000000000001253","article-title":"Acute-on-Chronic Liver Failure Incited by Cyclin-Dependent Kinase Inhibitor Therapy for Breast Cancer Effectively Treated With Liver Transplantation","volume":"11","author":"Kalas","year":"2024","journal-title":"ACG Case Rep J"},{"key":"2026100509101515000_19.10.e268777.20","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1111\/tbj.14238","article-title":"Fatal acute hepatic failure secondary to thrombotic portal venopathy after commencing abemaciclib and fulvestrant treatment for advanced breast carcinoma: a unique autopsy finding","volume":"27","author":"Haynes","year":"2021","journal-title":"Breast J"},{"key":"2026100509101515000_19.10.e268777.21","unstructured":"LiverTox: clinical and research information on drug-induced liver injury. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases, 2012."},{"key":"2026100509101515000_19.10.e268777.22","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.jare.2016.04.001","article-title":"Aromatase inhibitors induced autoimmune disorders in patients with breast cancer: A review","volume":"7","author":"Zarkavelis","year":"2016","journal-title":"J Adv Res"},{"key":"2026100509101515000_19.10.e268777.23","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.15992"},{"key":"2026100509101515000_19.10.e268777.24","doi-asserted-by":"crossref","first-page":"3087","DOI":"10.1200\/JCO.2024.42.16_suppl.3087","article-title":"An exploratory study on prediction of risk for abemaciclib-induced interstitial lung disease or hepatotoxicity by specific human leukocyte antigen alleles","volume":"42","author":"Imamura","year":"2024","journal-title":"JCO"},{"key":"2026100509101515000_19.10.e268777.25","unstructured":"Guidance for industry drug-induced liver injury: premarketing clinical evaluation drug safety. 2009. Available: https:\/\/www.fda.gov\/media\/116737\/download"},{"key":"2026100509101515000_19.10.e268777.26","unstructured":"Lilly E . VERZENIO\u00ae (abemaciclib) tablets, for oral use. Silver Spring (MD): U.S. Food and Drug Administration, 2025. Available: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/208716s019lbl.pdf"},{"key":"2026100509101515000_19.10.e268777.27","unstructured":"Oncology News Central . Abemaciclib: uses, dosing, warnings, adverse events, interactions. 2024. Available: https:\/\/www.oncologynewscentral.com\/drugs\/monograph\/174190-317058\/abemaciclib-oral"},{"key":"2026100509101515000_19.10.e268777.28","doi-asserted-by":"publisher","DOI":"10.1111\/tbj.13532"},{"key":"2026100509101515000_19.10.e268777.29","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2020.10.007"},{"key":"2026100509101515000_19.10.e268777.30","doi-asserted-by":"crossref","first-page":"433","DOI":"10.3138\/canlivj-2021-0015","article-title":"Palbociclib-induced severe hepatitis: A case study and literature review","volume":"4","author":"Hyppolite","year":"2021","journal-title":"Can Liver J"},{"key":"2026100509101515000_19.10.e268777.31","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhepr.2024.101098","article-title":"CDK4\/6 inhibitor-induced liver injury: Clinical phenotypes and role of corticosteroid treatment","volume":"6","author":"Meunier","year":"2024","journal-title":"JHEP Rep"},{"key":"2026100509101515000_19.10.e268777.32","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.iliver.2023.06.001","article-title":"Prednisolone therapy accelerates recovery of severe drug-induced liver injury: A prospective, randomized controlled study","volume":"2","author":"Song","year":"2023","journal-title":"ILIVER"},{"key":"2026100509101515000_19.10.e268777.33","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.820724","article-title":"Role of Corticosteroids in Drug-Induced Liver Injury. A Systematic Review","volume":"13","author":"Bj\u00f6rnsson","year":"2022","journal-title":"Front Pharmacol"},{"key":"2026100509101515000_19.10.e268777.34","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1111\/apt.17373","article-title":"Potential benefit and lack of serious risk from corticosteroids in drug-induced liver injury: An international, multicentre, propensity score-matched analysis","volume":"57","author":"Niu","year":"2023","journal-title":"Aliment Pharmacol Ther"},{"key":"2026100509101515000_19.10.e268777.35","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1159\/000322298","article-title":"Steroid and Ursodesoxycholic Acid Combination Therapy in Severe Drug-Induced Liver Injury","volume":"84","author":"Wree","year":"2011","journal-title":"Digestion"},{"key":"2026100509101515000_19.10.e268777.36","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.744488","article-title":"Role of Ursodeoxycholic Acid in Treating and Preventing Idiosyncratic Drug-Induced Liver Injury. A Systematic Review","volume":"12","author":"Robles-D\u00edaz","year":"2021","journal-title":"Front Pharmacol"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2025-268777","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T16:10:30Z","timestamp":1791216630000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2025-268777"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":36,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,10,5]]},"published-print":{"date-parts":[[2026,10]]}},"alternative-id":["10.1136\/bcr-2025-268777"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2025-268777","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10]]}}}